A Digital Health System to Assist Family Physicians to Safely Prescribe NOAC Medications

Samina Raza Abidi1, Jafna Cox2, Ashraf Abusharekh3

  • 1Medical Informatics, Faculty of Medicine, Dalhousie University.

Insights

Physicians can now use a new system to easily determine patient eligibility for New Oral Anticoagulants (NOACs) for atrial fibrillation (AF). This tool simplifies the special authorization process, improving patient care.

Area of Science:

  • Cardiology
  • Health Informatics
  • Medical Decision Support

Background:

  • Atrial Fibrillation (AF) is a prevalent cardiac arrhythmia.
  • Current anticoagulant therapies, including New Oral Anticoagulants (NOACs), are underutilized due to complex prescription processes.
  • Canada's provincial Pharmacare programs require a tedious, paper-based special authorization for NOACs, hindering optimal AF management.

Purpose of the Study:

  • To develop a computerized system to aid physicians in prescribing NOACs for AF.
  • To streamline the NOAC special authorization process for patients in Canadian provincial benefits programs.
  • To improve the quality of AF care by facilitating NOAC access.

Main Methods:

  • Development of a NOAC Authorization Decision Support System (NOAC-ADSS).
  • Utilizing semantic web technologies and ontologies to model NOAC eligibility criteria.
  • Implementing a system to execute knowledge for determining patient eligibility and dosage.

Main Results:

  • The NOAC-ADSS provides physicians with a tool to assess patient eligibility for NOACs based on Canadian AF guidelines.
  • The system assists in completing the special authorization form, reducing administrative burden.
  • Ontological modeling enables accurate and efficient determination of NOAC eligibility and dosage.

Conclusions:

  • The NOAC-ADSS offers a practical solution to the challenges in prescribing NOACs for AF patients.
  • This system has the potential to optimize AF care by improving access to effective anticoagulant therapy.
  • Digitalizing the authorization process can significantly enhance physician efficiency and patient outcomes.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
453
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
363
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
135